Stem cells in brain tumorigenesis and their impact on therapy

Current Stem Cell Research and Therapy

Volumn 6, Issue 4, 2011, Pages 339-349

  Cardona, Andrés Felipe ^a,b   Balañá, Carmen ^c   Torres, Diana ^d   Becerra, Henry ^a,b   Ortíz, León Darío ^b,e   Fadul, Camilo E ^b,f  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^b RedLANO ONCOLGroup   (Colombia)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^e Clinica Las Americas   (Colombia)

^f NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Brain tumor; Central nervous system neoplasms; Development; Genetics; Glioma; Medulloblastoma; Molecular biology; Neurogenesis; Stem cells; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD133 ANTIGEN; CEDIRANIB; CHLORAL HYDRATE; CHLORAMPHENICOL; CILENGITIDE; CYCLOPAMINE; DISULFIRAM; ENDOTHELIAL CELL GROWTH FACTOR; EVEROLIMUS; IMATINIB; ISOTRETINOIN; NBT 272; NOTCH1 RECEPTOR; OLIGODENDROCYTE LINEAGE TRANSCRIPTION FACTOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAPAMYCIN; RETINOIC ACID; RIDAFOROLIMUS; TANESPIMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; BRAIN NERVE CELL; BRAIN TUMORIGENESIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; GLIA; GLIOBLASTOMA; GLIOMA; HUMAN; MEDULLOBLASTOMA; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

EID: 80055118669     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488811797904317     Document Type: Article

References (108)

1. CBTRUS 2000-2004 data. United States population estimates by 5-year age group were obtained from United States census; esti mates available at www.census.gov.
2. Ries LAG, Melbert D, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2008.
3. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and PrevalenceWorldwide, Version 2.0. IARC CancerBase No. 5. Lyon, IARCPress, 2004. Limited version available from: URL: http://www_depdb.iarc.fr/globocan2002.htm
4. Stupp R, Roila F; ESMO Guidelines Working Group. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): 83-5.
5. Gilbert MR. Designing clinical trials for brain tumors: the next generation. Curr Oncol Rep 2007; 9: 49-54.
6. Buckner JC. Factors influencing survival in high grade gliomas. Semin Oncol 2003; 30: 10-4.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
8. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-8.
9. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7: 733-6.
10. Nam DH, Park K, Suh YL, et al. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 2004; 11: 863-9.
11. Knizetova P, Darling JL, Bartek J. Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. J Cell Mol Med 2008; 12: 111-25.
12. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
13. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
14. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 1997; 3: 730-7.
15. Nottebohm F. Neuronal replacement in adulthood. Ann NY Acad Sci 1985; 457:143-61.
16. Lie DC, Song H, Colamarino SA, et al. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol 2004; 44: 399-421.
17. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005; 28: 223-50.
18. Doetsch F, Caille I, Lim DA, et al. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999; 97: 703-16.
19. Morshead CM. Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron 1994; 13: 1071-82.
20. Sanai N, Tramontin AD, Quiñones-Hinojosa A, et al. Unique as-trocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 2004; 427: 740-4.
21. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 2007; 17: 5046-61.
22. Guerrero H, Chaichana K, Quiñones A, et al. Neurosphere culture and human organotypic model to evaluate brain tumor stem cells. Can Stem Cell 2009; 568(6): 73-83.
23. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-21.
24. Kania G, Corbeil D, Fuchs J. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell derived progenitors. Stem Cells 2001; 23: 791-804.
25. Singh SK, Hawkins C, Clarke ID. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
26. Bao S, Wu Q, McLendon RE. Glioma stem cells promote radiore-sistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
27. Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007; 67: 8980-4.
28. Liu G, Yuan X, Zeng Z. Analysis of gene expression and chemore-sistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67-78.
29. Jin F, Zhao L, Guo YJ, et al. Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. Brain Res 2010; 8(1336): 103-11.
30. Wang J, Sakariassen P, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Can 2008; 122: 761-8.
31. Ogden A, Waziri A, Lochhead R. Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62: 505-15.
32. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-90.
33. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006; 426: 425-36.
34. Dell'Albani P. Stem cell markers in gliomas. Neurochem Res 2008; 33: 2407-15.
35. Gu H, Wang S, Messam CA, et al. Distribution of nestin im-munoreactivity in the normal adult human forebrain. Brain Res 2002; 943: 174-80.
36. Holmin S, Almquist P, Lendahl U. Adult nestin expressing subependymal cells differentiate to astrocytes in response to brain injury. Eur J Neuro Sci 1997; 9: 65-75.
37. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992; 52: 5334-41.
38. Zhenju J, Lenhard R. Telomeres and telomerase in cancer stem cell. Eur J Cancer 2006; 42: 1197-203.
39. Bi C, Fang J, Chen F, et al. Chemoresistance of CD133(+) tumor stem cells from human brain glioma. Zhong Nan Da 2007; 32(4): 568-73.
40. Reilly K, Loisel D, Bronson R, et al. Nf1; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000; 26: 109-13.
41. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002; 1: 269-77.
42. Erlandsson A, Enarsson M, Forsberg-Nilsson K. Immature neurons from CNS stem cells proliferate in response to platelet-derived growth factor. J Neurosci 2001; 21: 3483-91.
43. Ligon KL, Huillard E, Mehta S, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007; 53: 503-17.
44. Yoon K. Mind bomb 1-expressing intermediate progenitors generate notch signaling to maintain radial glial cells. Neuron 2008; 58: 519-31.
45. Mizutani K, Yoon K, Dang L, et al. Differential Notch signalling distinguishes neural stem cells from intermediate progenitors. Nature 2007; 449: 351-5.
46. Corbin J. Regulation of neural progenitor cell development in the nervous system. J Neurochem 2008; 106: 2272-87.
47. Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci 2005; 8: 709-15.
48. Hoeck J, Jandke A, Blake S, et al. Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat Neurosc 2010; 13: 1365-72.
49. Hitoshi S, Seaberg RM, Koscik C, et al. Primitive neural stem cells from the mammalian epiblast differentiate to definitive neural stem cells under the control of Notch signalling. Genes Dev 2004; 18: 1806-11.
50. Ferrari G, Bonini S, Uberti D, et al. Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro Oncol 2010; 12(12): 1231-43.
51. Tanigaki K, Nogaki F, Takahashi J. Notch1 and Notch3 instructively restrict bFGF-responsive multipotent neural progenitor cells to an astroglial fate. Neuron 2001; 29: 45-55.
52. Zhang XP, Zheng G, Zou L. Notch activation promotes cell proliferation and the formation of neural stem-like colonies in human glioma cells. Mol Cell Bioch 2008; 307: 101-8.
53. Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005; 65: 2353-63.
54. Miele L. Notch Signaling. Clin Can Res 2006; 12: 1074-79.
55. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
56. Assanah M. Lochhead, Ogden A, et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 2006; 26: 6781-90.
57. Ayuso A, Moliterno JA, Kratovac S, et al. Activated EGFR signaling increases proliferation, survival, and migration and blocks neu-ronal differentiation in post-natal neural stem cells. J Neurooncol 2010; 97(3): 323-37.
58. Garcion E, Halilagic A, Faissner A, et al. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development 2004; 131: 3423-32.
59. Scadden DT. The stem-cell niche as an entity of action. Nature 2006; 441: 1075-79.
60. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Can 2008; 8: 755-68.
61. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
62. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77: 362-72.
63. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-33.
64. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-48.
65. Vredenburgh J, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25(30): 4722-9.
66. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vascu-lature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
67. Batchelor T, Duda D, di Tomaso E, et al. Phase II Study of Cedira-nib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Ty-rosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. J Clin Oncol 2007; 25(30): 4722-9.
68. Loges S, Butzal M, Otten J, et al. Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 2007; 357: 1016-20.
69. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-8.
70. Tabatabai G, Weller M, Nabors B, et al. Targeting integrins in malignant glioma. Target Oncol 2010; 5(3): 175-81.
71. Shaifer CA, Huang J, Lin PC. Glioblastoma cells incorporate into tumor vasculature and contribute to vascular radioresistance. Int J Cancer 2010; 127(9): 2063-75.
72. Sotelo C. Cellular and genetic regulation of the development of the cerebellar system. Prog Neurobiol 2004; 72: 295-339.
73. Fan X, Eberhart CG. Medulloblastoma Stem Cells. J Clin Oncol 2008; 26: 2821-7.
74. Wang VY, Rose MF, Zoghbi HY. Math1 expression redefines the rhombic lip derivatives and reveals novel lineages within the brain-stem and cerebellum. Neuron 2005; 48: 31-43.
75. Lee Y, Miller HL, Jensen P. A molecular fingerprint for medul-loblastoma. Cancer Res 2003; 63: 5428-37.
76. Dahmane N, Sanchez P, Gitton Y. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001; 128: 5201-12.
77. Yang Z, Ellis T, Markant S, et al. Medulloblastoma Can Be Initiated by Deletion of Patched in Lineage-Restricted Progenitors or Stem Cells. Can Cell 2008; 14(2): 135-45.
78. Sasai K, Romer JT, Kimura H. Medulloblastomas derived from CXCR6 mutant mice respond to treatment with a smoothened inhibitor. Cancer Res 2007; 67: 3871-7.
79. Schuller U, Rowitch DH. Beta-catenin function is required for cerebellar morphogenesis. Brain Res 2007; 1140: 161-9.
80. Koch A, Hrychyk A, Hartmann W. Mutations of the Wnt antagonist AXIN2 (conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer 2007; 121: 284-91.
81. Clifford SC, Lusher ME, Lindsey JC. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006; 5: 2666-70.
82. Dakubo GD, Mazerolle CJ, Wallace VA. Expression of Notch and Wnt pathway components and activation of Notch signaling in me-dulloblastomas from heterozygous patched mice. J Neurooncol 2006; 79: 221-7.
83. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-72.
84. Read T, Fogarty M, Markant S, et al. Identification of CD15 as a Marker for Tumor-Propagating Cells in a Mouse Model of Medul-loblastoma. Can Cell 2009: 15: 135-47.
85. Beier D, Wischhusen J, Dietmaier W, et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008; 18: 370-7.
86. Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 2008; 27: 85.
87. Pallini R, Ricci L, Banna G, et al. Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme. Clin Cancer Res 2008; 14: 8205-12.
88. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003; 3: 338-43.
89. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006; 17: 1620-4.
90. Nicolis SK. Cancer stem cells and stemness genes in neuro-oncology. Neurobiol Dis 2007; 25: 217-29.
91. Clement V, Sanchez P, de Tribolet N, et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17: 165-72.
92. Chearwae W, Bright JJ. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer 2008; 99: 2044-53.
93. Beier D, Röhrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008; 68: 5706-15.
94. Guzman ML. The sesquiterpene lactone parthenolide induces apop-tosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163-9.
95. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444: 761-5.
96. Dresemann G, Hosius C, Lilienthal J, et al. Treatment failure due to intracerebral stem cell-like behavior of glioblastoma (GB) cells: A reason for targeted maintenance therapy with imatinib (I) and hydroxyurea (H)? An analysis of study DE21 and DE40 (Ambrosia). J Clin Oncol 2008; 26: 2048[Abstr].
97. Abouantoun TJ, Macdonald TJ. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Mol Cancer Ther 2009; 5: 1-19.
98. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345-9.
99. Hambardzumyan D, Becher OJ, Rosenblum MK, et al. PI3K pathway regulates survival of cancer stem cells residing in the perivas-cular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22: 436-48.
100. Lu J, Zhang F, Zhao D, et al. ATRA-inhibited proliferation in glioma cells is associated with subcellular redistribution of beta-catenin via up-regulation of Axin. J Neurooncol 2008; 87: 271-7.
101. Spiller SE, Ditzler SH, Pullar BJ, et al. Response of preclinical medulloblastoma models to combination therapy with 13-cis reti-noic acid and suberoylanilide hydroxamic acid (SAHA). J Neu-rooncol 2008; 87: 133-41.
102. Elisabeth CM, Leigh J, Kesari S, et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 2009; 11: 109-21.
103. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblas-toma. Stem Cells 2007; 25: 2524-33.
104. Lee J, Son MJ, Woolard K, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008; 13: 69-80.
105. Di Tomaso T, Mazzoleni S, Wang E, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010; 16: 800-13.
106. Xu Q, Liu G, Yuan X, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009; 27: 1734-40.
107. Castellino R, Muh C, Durden D. PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis. Curr Pharm Des 2009; 15(4): 380-8.
108. Kast R, Belda C. Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct. Curr Stem Cell Res Ther 2009; 4: 314-7.